Navigation Links
WellPoint Announces Second Annual Innovation Event
Date:11/13/2008

re informed consumers of health care."

This year's Innovation Event will be focused on engagement, specifically those solutions that improve consumer and provider engagement. Solutions that address ways to control costs through more informed consumers and health care providers, while maintaining quality care, will be given the highest consideration.

"Last year, our goal was to identify at least one organization as a potential partner for an in-market pilot program," Pomeroy said. "The results exceeded our expectations as several attractive opportunities were identified. We continue to explore potential partnerships with these companies and recently signed a letter of agreement with one of them, MedVantx, a pharmaceutical delivery company. We look forward to deploying their unique business model initially in our Kentucky and Ohio markets."

Those companies interested in participating need to complete and submit an application. All applications will be screened and the top submissions will receive an invitation to attend the Innovation Event in March 2009. Companies selected to participate will be notified beginning in late January.

To request an application, please send an e-mail to innovation@WellPoint.com with a subject header of "Application Request - 2009 Innovation Event," and include company name, point of contact, address and phone number.

About WellPoint, Inc.

WellPoint, Inc. is the largest health benefits company in terms of medical membership in the United States. WellPoint is an independent licensee of the Blue Cross and Blue Shield Association and serves its members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as the Blue Cross Blue Shield licensee in 10 New York City metropolitan and surrounding counties and as the Blue Cross
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. WellPoint Congratulates President-Elect Barack Obama
2. WellPoint Awarded Prestigious International Marketing Award
3. WellPoint President and CEO Angela Braly Appears at the Norfolk Forum
4. WellPoint Announces Appearances at Upcoming Conferences
5. WellPoint Reports Third Quarter 2008 Results
6. WellPoints Dr. Alan Rosenberg to Address Industrys Top Medical Technology Conference
7. WellPoint Adjusts Health and Pharmacy Guidelines for Members in Texas and Louisiana Affected by Hurricane Ike
8. WellPoint Announces Appointments of Lori Beer as Executive Vice President and Chief Information Officer; Martin Miller as Senior Vice President, Chief Accounting Officer and Controller
9. WellPoint Appoints Krista A. Bowers as President of Senior Business
10. WellPoint Foundation Awards $2.5 Million Grant to The CoverMe Foundation
11. WellPoint Partners With CareNex Health Services to Expand Its Neonatal Intensive Care Services Program
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 1VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 2VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 1VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 1Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 3